Tango Therapeutics Files 2024 10-K

Ticker: TNGX · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1819133

Sentiment: neutral

Topics: 10-K, pharmaceuticals, annual-report

TL;DR

Tango Tx 2024 10-K is IN. Full financials and biz details out now.

AI Summary

Tango Therapeutics, Inc. filed its 2024 10-K on February 27, 2025, reporting on its fiscal year ending December 31, 2024. The company, formerly BCTG Acquisition Corp., is focused on pharmaceutical preparations and is incorporated in Delaware. Key financial details and operational highlights for the fiscal year are detailed within the filing.

Why It Matters

This filing provides investors and stakeholders with a comprehensive overview of Tango Therapeutics' financial health, operational performance, and strategic direction for the fiscal year 2024.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Tango Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is Tango Therapeutics' primary business activity?

Tango Therapeutics, Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].

When did Tango Therapeutics change its name from BCTG Acquisition Corp.?

The date of the name change from BCTG Acquisition Corp. to Tango Therapeutics was July 23, 2020.

What is the fiscal year end for Tango Therapeutics?

The fiscal year end for Tango Therapeutics is December 31st.

Where is Tango Therapeutics headquartered?

Tango Therapeutics is headquartered in Boston, MA, with its business and mail address listed as 201 Brookline Avenue, Suite 901, Boston, MA 02215.

What is the filing date of this 10-K report?

This 10-K report was filed on February 27, 2025.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Tango Therapeutics, Inc. (TNGX).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing